Related Experiment Videos

CTLA-4 +49A>G polymorphism is associated with advanced non-small cell lung cancer prognosis

Bao Song1, Yanbing Liu, Jie Liu

  • 1Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Academy of Medical Sciences, Jinan, China.

Respiration; International Review of Thoracic Diseases
|August 12, 2011
PubMed
Abstract

Insights

The CTLA-4 +49A>G gene polymorphism is linked to prognosis in advanced non-small cell lung cancer (NSCLC). Patients with the AA genotype show significantly shorter survival, indicating it

Area of Science:

  • Immunogenetics
  • Oncology
  • Molecular Biology

Background:

  • Cytotoxic T lymphocyte antigen 4 (CTLA-4) is a key regulator of T cell activation, crucial in immune responses.
  • The CTLA-4 +49A>G polymorphism is known to be associated with autoimmune diseases.
  • The prognostic significance of this CTLA-4 polymorphism in cancer, particularly NSCLC, remains largely unexplored.

Purpose of the Study:

  • To evaluate the association between the CTLA-4 +49A>G polymorphism and the prognosis of advanced non-small cell lung cancer (NSCLC).
  • To investigate the CTLA-4 +49A>G polymorphism as a potential predictive biomarker in a Chinese NSCLC patient cohort.

Main Methods:

  • Genotyping of the CTLA-4 +49A>G polymorphism was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
  • The study included 338 patients diagnosed with advanced non-small cell lung cancer.
  • Statistical analyses, including log-rank test and multivariate Cox regression, were employed to assess survival outcomes.

Main Results:

  • The frequencies of CTLA-4 +49 GG, GA, and AA genotypes were 44.4%, 42.0%, and 13.6%, respectively.
  • No significant correlation was found between the CTLA-4 +49A>G polymorphism and clinicopathological features of NSCLC.
  • Patients with the AA genotype exhibited a significantly shorter median survival (9.8 months) compared to GG (12.5 months) and GA (12.0 months) genotypes (p < 0.001).
  • Multivariate analysis identified the CTLA-4 +49AA genotype as an independent adverse prognostic factor for NSCLC.

Conclusions:

  • The CTLA-4 +49A>G polymorphism serves as a significant prognostic predictor in patients with advanced non-small cell lung cancer.
  • This genetic variation may aid in stratifying NSCLC patients for risk assessment and potentially personalized treatment strategies.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...